On December 12, 2022 Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, reported that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022 (Press release, Applied DNA Sciences, DEC 12, 2022, View Source [SID1234625081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s management will host a conference call with investors and covering analysts starting at 4:30 pm ET that same day. On the call, Chief Financial Officer Beth Jantzen and President and CEO Dr. James A. Hayward will discuss the Company’s quarterly financial performance and recent accomplishments, followed by a question-and-answer session.

To access the conference call:

U.S. callers should dial 1-844-887-9402, and international callers should dial +1-412-317-6798 approximately five minutes before the call begins.
Participants should ask to be connected to the Applied DNA Financial Results conference call.
You can listen to the call and view the accompanying exhibits on Applied DNA’s investor relations website at View Source at the scheduled time. A webcast replay of the call will also be available on the investor relations website approximately one hour after the end of the call.